£141.69

Academic Press Biology of T Cells - Part A (Volume 341) (International Review of Cell and Molecular Biology, Volume 341)

Price data last checked 91 day(s) ago - refreshing...

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

About as cheap as it gets. The only time it was cheaper was 9 months ago.

£142 today · all-time low £139 (Sep 2025) · usually the usual

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey
↓ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 314 days • 314 data points (No recent data available)

Historical
Generating forecast...
£149.69 £138.33 £140.81 £143.29 £145.76 £148.24 £150.72 01 May 2025 18 July 2025 04 October 2025 21 December 2025 10 March 2026

Price Distribution

Price distribution over 314 days • 5 price levels

Days at Price
Current Price
133 days 101 days · current 20 days 20 days 40 days 0 33 67 100 133 £139 £141 £143 £147 £150 Days at Price

Price Analysis

Most common price: £139 (133 days, 42.4%)

Price range: £139 - £150

Price levels: 5 different prices over 314 days

Description

Biology of T Cells: Part A, Volume 341, the latest release in the International Review of Cell and Molecular Biology, reviews and details current advances in cell and molecular biology. The IRCMB series maintains the highest standard by publishing timely topics authored by prominent cell and molecular biologists. Specialized topics in this release include TCR signaling: Molecules and mechanisms, TCR diversity: Purpose and generation, Transcriptional programs underlying T-cell differentiation and function, Surface phenotypes of CD8+ and CD4+ T cells, Co-stimulation and co-inhibition in CD8+ and CD4+ T cells, Regulated cell death and T cells, Molecular mechanisms behind T-cell priming by DCs, and more. Publishes only invited review articles on selected topicsAuthored by established and active cell and molecular biologists and drawn from international sourcesOffers a wide range of perspectives on specific subjects Review The only multi-volume review series that publishes comprehensive and detailed reviews of the current advances in cell and molecular biology About the Author Lorenzo Galluzzi (born 1980) is currently Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College (New York, USA), and Honorary Associate Professor at the Faculty of Medicine of the Paris Descartes University (Paris, France).Prior to joining Weill Cornell Medical College (2017), Lorenzo Galluzzi was a Junior Scientist of the Research Team “Apoptosis, Cancer and Immunity at the Cordeliers Research Center (Paris, France; 2012-2016). Lorenzo Galluzzi did his post-doctoral training at the Gustave Roussy Cancer Center (Villejuif, France; 2009-2011), after receiving his PhD from the Paris Sud University (Le Kremlin-Bicetre, France; 2005-2008). He is also Associate Director of the European Academy for Tumor Immunology (EATI), and Founding Member of the European Research Institute for Integrated Cellular Pathology (ERI-ICP).Lorenzo Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. In particular, he provided profound insights into the links between adaptive stress responses in cancer cells and the activation of a clinically relevant tumor-targeting immune response in the context of chemotherapy and radiation therapy. Lorenzo Galluzzi has published more than 350 scientific articles in international peer-reviewed journals. According to a survey published by Lab Times, he is currently the 6th and the youngest of the 30 most-cited European cell biologists (relative to the period 2007-2013).Lorenzo Galluzzi currently operates as Editor-in-Chief of three journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, and Molecular and Cellular Oncology (which he co-founded in 2013). In addition, Lorenzo Galluzzi currently serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease.Nils-Petter Rudqvist received his M.Sc. (Physics, 2009) and Ph.D. (Medical Science, 2015) from the University of Gothenburg, Sweden. He decided to pursue an academic career and continue with his postdoctoral training in US. He first joined the Center for Radiological Research at Columbia University in New York where he studied gene signatures of radiation exposure. He then moved to Weill Cornell Medicine to join the program in radiation and immunity under the mentorship of Dr. Demaria. His current research is focused on investigating which neoantigens are key targets of the radiation-induced anti-tumor T cell response in mice and in patients treated with radiotherapy and immune checkpoint blockade. He recently demonstrated in a mouse model that radiation therapy diversifies the TCR repertoire of tumor infiltrating lymphocytes, an effect crucial for its synergy with immune checkpoi

Product Specifications

Format
hardcover
Domain
Amazon UK
Release Date
02 October 2018
Listed Since
16 March 2018

Barcode

No barcode data available

Similar Products You Might Like

Biology of T Cells - Part B: Volume 342 (International Review of Cell and Molecular Biology, Volume 342)
99% match

Biology of T Cells - Part B: Volume 342 (International Review of Cell and Molecular Biology, Volume 342)

Academic Press

£170.59 13 Apr 2026
Academic Press Tumor Immunology and Immunotherapy Vol 636
98% match

Academic Press Tumor Immunology and Immunotherapy Vol 636

Academic Press

£135.85 19 Apr 2026
Tumor Immunology and Immunotherapy - Integrated Methods Part A: Volume 635 (Methods in Enzymology, Volume 635)
98% match

Tumor Immunology and Immunotherapy - Integrated Methods Part A: Volume 635 (Methods in Enzymology, Volume 635)

Academic Press

£134.49 01 Mar 2026
Tumor Immunology and Immunotherapy – Cellular Methods Part A (Volume 631) (Methods in Enzymology, Volume 631)
98% match

Tumor Immunology and Immunotherapy – Cellular Methods Part A (Volume 631) (Methods in Enzymology, Volume 631)

Academic Press

£135.59 09 Mar 2026
Cancer Stem Cell Resistance to Targeted Therapy: 19 (Resistance to Targeted Anti-Cancer Therapeutics, 19)
96% match

Cancer Stem Cell Resistance to Targeted Therapy: 19 (Resistance to Targeted Anti-Cancer Therapeutics, 19)

Springer

£75.84 28 Feb 2026
Clinical Immuno-Oncology
96% match

Clinical Immuno-Oncology

Elsevier

£92.99 25 Jan 2026
Immunotherapy in Translational Cancer Research (Translational Oncology)
96% match

Immunotherapy in Translational Cancer Research (Translational Oncology)

Wiley

£135.04 24 Jan 2026
Successes and Challenges of NK Immunotherapy: Breaking Tolerance to Cancer Resistance
96% match

Successes and Challenges of NK Immunotherapy: Breaking Tolerance to Cancer Resistance

Academic Press

£98.89 09 Mar 2026
Immunotherapy of Cancer: Methods and Protocols: 651 (Methods in Molecular Biology, 651)
96% match

Immunotherapy of Cancer: Methods and Protocols: 651 (Methods in Molecular Biology, 651)

Humana

£73.91 07 Mar 2026
Cancer Immunotherapy: Immune Suppression and Tumor Growth
96% match

Cancer Immunotherapy: Immune Suppression and Tumor Growth

Academic Press

£77.00 24 Feb 2026
Cancer Immunotherapy: Immune Suppression and Tumor Growth
96% match

Cancer Immunotherapy: Immune Suppression and Tumor Growth

Academic Press

£78.99 23 Feb 2026
Cancer Immunology: Innovative Approaches to Therapy: 27 (Cancer Treatment and Research, 27)
96% match

Cancer Immunology: Innovative Approaches to Therapy: 27 (Cancer Treatment and Research, 27)

Springer

£176.00 09 Apr 2026
Current Immunotherapeutic Strategies in Cancer: 214 (Recent Results in Cancer Research, 214)
96% match

Current Immunotherapeutic Strategies in Cancer: 214 (Recent Results in Cancer Research, 214)

Springer

£87.93 12 Apr 2026
Tumor Immunology: Methods and Protocols: 1393 (Methods in Molecular Biology, 1393)
96% match

Tumor Immunology: Methods and Protocols: 1393 (Methods in Molecular Biology, 1393)

Humana

£68.79 06 Mar 2026
Tumor Antigens Recognized by T Cells and Antibodies: 3 (Tumour Immunology and Immunotherapy Series)
96% match

Tumor Antigens Recognized by T Cells and Antibodies: 3 (Tumour Immunology and Immunotherapy Series)

CRC Press

£188.36 08 Mar 2026
Cancer Immunology: Innovative Approaches to Therapy: 27 (Cancer Treatment and Research, 27)
96% match

Cancer Immunology: Innovative Approaches to Therapy: 27 (Cancer Treatment and Research, 27)

Springer

£146.40 24 Feb 2026
Springer - Immunotherapy of Cancer: An Innovative Treatment
96% match

Springer - Immunotherapy of Cancer: An Innovative Treatment

Springer

£110.34 18 Apr 2026
Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy: 1036 (Advances in Experimental Medicine and Biology, 1036)
96% match

Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy: 1036 (Advances in Experimental Medicine and Biology, 1036)

Springer

£96.55 09 Mar 2026
Immunodiagnosis and Immunotherapy of Malignant Tumors: Relevance to Surgery
96% match

Immunodiagnosis and Immunotherapy of Malignant Tumors: Relevance to Surgery

Springer

£89.36 08 Mar 2026
Developments in T Cell Based Cancer Immunotherapies (Cancer Drug Discovery and Development)
96% match

Developments in T Cell Based Cancer Immunotherapies (Cancer Drug Discovery and Development)

Humana

£112.39 31 Jan 2026
Targeted Cancer Immune Therapy
95% match

Targeted Cancer Immune Therapy

Springer

£145.51 11 Jan 2026
Diagnostic Pathology: Molecular Oncology
95% match

Diagnostic Pathology: Molecular Oncology

Elsevier

£40.94 28 Jan 2026
Immune-based Cancer Treatment: The T Iymphocyte Response
95% match

Immune-based Cancer Treatment: The T Iymphocyte Response

CRC Press

£67.80 26 Feb 2026
Critical Developments in Cancer Immunotherapy
95% match

Critical Developments in Cancer Immunotherapy

£421.00 12 Apr 2026